XML 24 R11.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue Recognition
 6 Months Ended
Jun. 30, 2020
Revenue from Contract with Customer [Abstract]  
Revenue Recognition Revenue Recognition
During the three and six months ended June 30, 2020, the Company recognized total revenue under collaborative research and development and other agreements of $64,000 and $1.2 million, respectively, from its affiliated entity Plumbline Life Sciences, Inc. ("PLS"), $74,000 and $146,000, respectively, from AstraZeneca and $129,000 and $244,000, respectively, from various other contracts. Of the total revenue recognized during the three and six months ended June 30, 2020, $66,000 and $124,000, respectively, were in deferred revenue as of December 31, 2019. Performance obligations are generally satisfied within 12 months of the initial contract date.